Background: Intermediate clinical endpoints (ICEs) are frequently used as primary endpoint in randomised trials (RCTs). We aim to assess whether changes in different ICEs can be used to predict changes in overall survival (OS) in adjuvant breast cancer trials. Methods: Individual patient level data from adjuvant phase III RCTs conducted by the...
-
2024 (v1)PublicationUploaded on: July 3, 2024
-
2023 (v1)Publication
PURPOSECompared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer.METHODSThis retrospective study included PWH treated with anti-PD-1- or...
Uploaded on: January 31, 2024